Comprehensive Eyecare of Central Ohio, Westerville; Department of Ophthalmology, Ohio State University, Columbus.
Duke Eye Center, Durham, North Carolina.
J Cataract Refract Surg. 2019 Nov;45(11):1670-1679. doi: 10.1016/j.jcrs.2019.06.027.
Members of the ASCRS Cornea Clinical Committee performed a review of the current literature on the corneal crosslinking (CXL) procedure for treating corneal ectasia. The members explored the data on the techniques currently in use and under investigation, including their advantages, safety profiles, risks, and cost analyses, compared with data on corneal transplantation. They concluded that CXL limits the progression of keratoconus, thus reducing the need for transplantation. They also found that compared with permitting the disease to progress naturally, CXL techniques carry significant and long-term cost and safety benefits, primarily by reducing the need for corneal transplantation. Studies of various CXL techniques (eg, epithelium-on treatment, changes in ultraviolet light parameters, riboflavin composition) continue with the ultimate goal of improving the procedure's safety and efficacy.
美国白内障与屈光手术学会角膜临床委员会的成员对角膜交联术（CXL）治疗角膜扩张的现有文献进行了回顾。成员们探讨了目前正在使用和正在研究的技术的数据，包括它们的优势、安全性概况、风险和成本分析，并与角膜移植的数据进行了比较。他们得出结论，CXL 可以限制圆锥角膜的进展，从而减少移植的需求。他们还发现，与允许疾病自然进展相比，CXL 技术具有显著的长期成本和安全效益，主要是通过减少角膜移植的需求。对各种 CXL 技术（例如，上皮下治疗、紫外线参数变化、核黄素组成）的研究仍在继续，其最终目标是提高该手术的安全性和疗效。
